Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$0.12
$0.16
$1.57
$763K4.024,068 shsN/A
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
$11.25
-0.6%
$0.00
$1.22
$63,000.00
$450K-0.03771 shs723,270 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.08
$0.08
$0.06
$0.29
$1.03M0.57,619 shs13 shs
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
$2.02
-49.5%
$2.02
$2.02
$77.00
$521K1.12103 shs400 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%0.00%0.00%-99.40%-99.88%
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
+0.62%-9.80%-22.62%-2.67%+44.76%
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00%-17.89%-11.46%-9.20%-61.02%
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/AN/AN/AN/A
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00
N/AN/AN/A
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
0.00
N/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K0.00N/AN/A($2.43) per share0.00
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
$3.41M0.13N/AN/A($1,036.00) per share-0.01
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.03N/AN/A$0.57 per share0.14
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
$1.61M0.32N/AN/A($31.45) per share-0.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
-$19.22MN/A0.00N/A-1,546.38%N/A-343.56%N/A
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$0.78N/AN/A-8.35%-41.81%-9.56%9/22/2025 (Estimated)
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
-$4.80MN/A0.00N/A-450.40%N/A-777.68%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.10
0.01
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
N/A
0.53
0.50
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/A
0.12
0.12

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
0.16%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
N/A

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
4.20%
Dynatronics Co. stock logo
DYNT
Dynatronics
7.98%
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
5.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
104.74 million4.53 millionNot Optionable
Delcath Systems, Inc. stock logo
DCTHD
Delcath Systems
N/A40,000N/ANot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20013.18 million8.11 millionNot Optionable
H-CYTE, Inc. stock logo
HCYTD
H-CYTE
8258,000244,000Not Optionable

Recent News About These Companies

Telegram: What it is and how to use it
Chile launches new fast train service
Hydro One Limited (H.TO)
W.H. Hamilton Struck by a Train.
4-H Scholarships
H&R Block Coupons February 2024
Become a Volunteer
Hyatt Hotels Corp Class A H
4-H Youth Development
Robert H. Shea
H Samuel Discount Codes July 2023
Gallery - Salon H / Niimori Jamison Architects
Paul H. Wender, MD

Media Sentiment Over Time

Top Headlines

View All Headlines
Arch Therapeutics stock logo

Arch Therapeutics OTCMKTS:ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Delcath Systems stock logo

Delcath Systems OTCMKTS:DCTHD

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

$0.08 0.00 (0.00%)
As of 07/18/2025

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

H-CYTE stock logo

H-CYTE OTCMKTS:HCYTD

$2.02 -1.98 (-49.50%)
As of 07/11/2022

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.